Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Matrix Alliance to Speed Breakthrough Treatments to Market

By Magnolia Communications | February 17, 2016

Compatibility and testing of nested container and closure systems to help pharmaceutical companies manufacture parenteral medicines.

VANCOUVER, CANADA – As next-generation drugs require perfectly aligned manufacturing processes and packaging solutions, leading suppliers have announced the creation of the Matrix Alliance. Their mission is to bring to market complete and compelling solutions for aseptic filling, consisting of nest, stopper, cap and filling machinery to accelerate the adoption rate of breakthrough medicines.

The Alliance was formed on the initiative of Vanrx Pharmasystems with inaugural members ARaymond Life, Daikyo Seiko, Datwyler Group, Ompi, Schott AG, Schott Kaisha and SiO2 Medical Products. Each member brings unique knowledge and experience to the Alliance, as well as industry-leading products. As part of the collaboration, members will leverage the testing and certification of their combined offerings. The Alliance is also a forum providing strategic direction, education, and awareness of new aseptic packaging solutions within the membership and to the market.

The companies are collectively focused on pharmaceutical manufacturing and packaging technologies, and have reached an agreement to work in four key areas:

  • Testing of new pre-sterilized container and nested closure systems for parenteral (injectable) medicines
  • Ensuring the compatibility of components from different members
  • Driving industry awareness of those solutions
  • Collaborating on industry education regarding new medicine packaging solutions

“The need for collaboration in this area arises from the increasing sophistication of manufacturing processes and packaging needed for next-generation parenteral pharmaceuticals. Emerging categories of complex, high-value injectable drugs share the need for innovation in fill / finish and packaging. We believe that collaboration will speed the path of new therapies to the market by our customers, the pharmaceutical companies,” Alliance members said in a joint statement.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

This is the logo of Novartis.
Novartis breaks ground on North Carolina facility
AstraZeneca
AstraZeneca to invest $2B in Maryland, support 2,600 jobs
This is the logo of Novartis.
Novartis opens new manufacturing plant in California
samsung biologics (1)
Samsung Biologics completes Bioepis spinoff to become pure-play pharma CDMO
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE